PRISM BioLab Co.,LTD (TSE: 206A)
Health Care · Pharmaceuticals · JP
¥166.00
-0.60% today · -11.2% 1Y
PRISM BioLab Co.,LTD (TSE: 206A) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $38.56M and employs 35 people.
Over the last twelve months the share price has lost 11.2%, trading between 125.00 and 279.00.
Tweenvest scores PRISM BioLab Co.,LTD across four factors: quality 43/100, value 57/100. Its strongest factor is value.
206A price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $38.56M
- Revenue (TTM)
- $4.48M
- P/E
- —
- EPS
- -26.13
- Dividend yield
- —
- Beta (5Y)
- 1.43
- 52-week high
- ¥279.00
- 52-week low
- ¥125.00
- Avg volume (3M)
- —
- Shares outstanding
- 36.96M
- Employees
- 35
- Next earnings
- —
About PRISM BioLab Co.,LTD
PRISM Pharma Co., Ltd. is a pharmaceutical enterprise dedicated to identifying and advancing small molecule compounds. Its core mission involves modulating protein-protein interactions. The company leverages a proprietary protein secondary structure mimetic library to regulate interactions between proteins within cells. A key product in its development pipeline is PRI-724, an anti-cancer CP/Catenin inhibitor. This drug targets both mature cancer cells and cancer stem cells, inducing them to transition from uncontrolled proliferation to differentiation. Hiroyuki Kouji founded the organization on November 2, 2006, and it is headquartered in Fujisawa, Japan.
- ISIN
- JP3833190006
- Founded
- 2006
- Listed since
- Jul 2, 2024
- Exchange
- The Tokyo Stock Exchange
- Currency
- JPY
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,233.66 | -1.06% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $273.14 | +0.04% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $156.45 | +3.84% |
| Roche Holding AGSWX: ROP | $371.62B | CHF373.80 | +0.92% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £124.76 | +3.02% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.57 | +2.15% |
Figures last refreshed Aug 18, 2026.